Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q4 2022 · 10-K
Revenue$28.11M$28.11M−37.4% vs Q4 2021 Net Income-$55.18M-$55.18MderivedN/M vs Q4 2021 EPS Diluted-$1.88-$1.88N/M vs Q4 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
−28.5%
Operating Incomederived-$3,101,000N/M Operating Cash Flowderived-$1,852,000N/M Free Cash Flowderived-$9,539,000N/M Margins · derivedGross margin37.1%+4.6 pt vs Q4 2021
Operating margin-11.0%−11.8 pt vs Q4 2021
Net margin-196.3%−193.5 pt vs Q4 2021
ended May 29, 2022 · filed Sep 14, 2022 · 108 d after period end